Shares of biotech stock Zogenix had an exciting trading day on Friday after the company reported positive epilepsy drug test results. The company’s drug ZX008 succeeded in showing improvements in reducing seizures for patients that have Dravet syndrome in a Phase 3 trial. Shares increased by 180% in midday trading on Friday after the company … Continue reading “Zogenix Shares Double on Epilepsy Treatment Results”